Indication
Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when: The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Dectova should be used in accordance with official guidance.
Official EMA Resources
View on EMA (ema.europa.eu)AI Drug & Interaction Analysis
Free account required
Ask Prognia AI about Dectova — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.